This week we wrap up our series about repurposing drugs to fight COVID-19 with a brief overview of other drugs that are currently undergoing clinical trials. But that’s not all: we queried Monocl Professional to identify leading academic experts who have significant experience working with these drugs.
Read more
COVID-19 is a new disease and there is limited information regarding risk factors for severe disease. However, based on currently available information and clinical expertise, older adults and people of any age who have serious underlying medical conditions might be at higher risk for severe illness from COVID-19, including people with asthma and other lung diseases such as chronic obstructive pulmonary disease (COPD). In this week’s TTL, we review global experts and rising stars with asthma and COPD related research in relation to COVID-19.
Read more
Is COVID-19 creating a new normal for medical affairs and particularly medical science liaisons? In our blog we discuss the possible long-term ramifications of social distancing and instant digitalization on medical field teams.
Read more
In part 4 of our series about repurposed drugs to treat COVID-19 we are showcasing the first biologics: tocilizumab sold under the brand name Actemra and sarilumab, which is sold as Kevzara; both are monoclonal antibodies.
Read more
In part 3 of our series about repurposed drugs to treat COVID-19 we are showcasing Lopinavir/Ritonavir (Kaletra), an anti-viral drug used to fight HIV infections. It was approved in September 2000 in the US and March 2001 in the EU. By now generic versions of the lopinavir/ritonavir combination have also been approved by the FDA.
Read more
Most of us have to share their names with other people. If you have a common last and a popular first name you might have to share with quite a few. You aren’t likely to be confused by a baker in Nashville or a facilities manager in Suffolk but how about other scientists, physicians or researchers? In this blog we interview Monocl’s disambiguation expert Jiaji Wu about the challenge of finding the right John Smith.
Read more